Munshi Amit

SEC source: 0001209191-21-003703 · doc4.xml · nonDerivative · entry 3

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,750

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.

F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.36 to $76.14, inclusive.

SEC source: 0001209191-21-003703 · doc4.xml · nonDerivative · entry 2

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,146

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.36 to $75.35, inclusive.

SEC source: 0001209191-21-003703 · doc4.xml · nonDerivative · entry 1

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,627

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.34 to $74.18, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 3, and 4 to this Form 4.

SEC source: 0001209191-21-003165 · doc4.xml · derivative · entry 3

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 23,400 shares

Expires 2022-01-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On January 4, 2019, the Reporting Person was granted 23,400 target Performance Restricted Stock Units ("PRSUs"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon Arena's common stock reaching certain Nasdaq "Closing Price" thresholds during the 3-year performance period from Jan. 4, 2019, through Jan. 3, 2022 (the "Performance Period") and satisfaction of a subsequent continuing service requirement. 11,700 of the shares subject to the PRSUs vested in Oct. 2019 (50% of the target amount), and another 11,700 of the shares subject to the PRSUs (50% of the target amount) vested in Nov. 2020. The final 23,400 shares issuable pursuant to the PRSUs (200% of the target amount, less the 100% already vested) vested and released on January 7, 2021, as reported herein.

F1 · shares: On January 4, 2019, the Reporting Person was granted 23,400 target Performance Restricted Stock Units ("PRSUs"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon Arena's common stock reaching certain Nasdaq "Closing Price" thresholds during the 3-year performance period from Jan. 4, 2019, through Jan. 3, 2022 (the "Performance Period") and satisfaction of a subsequent continuing service requirement. 11,700 of the shares subject to the PRSUs vested in Oct. 2019 (50% of the target amount), and another 11,700 of the shares subject to the PRSUs (50% of the target amount) vested in Nov. 2020. The final 23,400 shares issuable pursuant to the PRSUs (200% of the target amount, less the 100% already vested) vested and released on January 7, 2021, as reported herein.

F1 · derivative.exercise_date: On January 4, 2019, the Reporting Person was granted 23,400 target Performance Restricted Stock Units ("PRSUs"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon Arena's common stock reaching certain Nasdaq "Closing Price" thresholds during the 3-year performance period from Jan. 4, 2019, through Jan. 3, 2022 (the "Performance Period") and satisfaction of a subsequent continuing service requirement. 11,700 of the shares subject to the PRSUs vested in Oct. 2019 (50% of the target amount), and another 11,700 of the shares subject to the PRSUs (50% of the target amount) vested in Nov. 2020. The final 23,400 shares issuable pursuant to the PRSUs (200% of the target amount, less the 100% already vested) vested and released on January 7, 2021, as reported herein.

F3 · derivative.underlying_shares: The amount reported in Column 7 of Table II represents the common shares that vested on January 7, 2021. The PRSUs have now fully vested and no common shares remain issuable thereunder.

F1 · balance_after: On January 4, 2019, the Reporting Person was granted 23,400 target Performance Restricted Stock Units ("PRSUs"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon Arena's common stock reaching certain Nasdaq "Closing Price" thresholds during the 3-year performance period from Jan. 4, 2019, through Jan. 3, 2022 (the "Performance Period") and satisfaction of a subsequent continuing service requirement. 11,700 of the shares subject to the PRSUs vested in Oct. 2019 (50% of the target amount), and another 11,700 of the shares subject to the PRSUs (50% of the target amount) vested in Nov. 2020. The final 23,400 shares issuable pursuant to the PRSUs (200% of the target amount, less the 100% already vested) vested and released on January 7, 2021, as reported herein.

SEC source: 0001209191-21-003165 · doc4.xml · nonDerivative · entry 2

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,627

F2 · shares: Represents the number of shares withheld by, and surrendered to, Arena relating to tax withholding in connection with the issuance of shares under the PRSUs.

SEC source: 0001209191-21-003165 · doc4.xml · nonDerivative · entry 1

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,150

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On January 4, 2019, the Reporting Person was granted 23,400 target Performance Restricted Stock Units ("PRSUs"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon Arena's common stock reaching certain Nasdaq "Closing Price" thresholds during the 3-year performance period from Jan. 4, 2019, through Jan. 3, 2022 (the "Performance Period") and satisfaction of a subsequent continuing service requirement. 11,700 of the shares subject to the PRSUs vested in Oct. 2019 (50% of the target amount), and another 11,700 of the shares subject to the PRSUs (50% of the target amount) vested in Nov. 2020. The final 23,400 shares issuable pursuant to the PRSUs (200% of the target amount, less the 100% already vested) vested and released on January 7, 2021, as reported herein.

SEC source: 0001209191-20-062473 · doc4.xml · nonDerivative · entry 1

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,750

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.02, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001209191-20-060717 · doc4.xml · derivative · entry 3

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,400

Underlying: Common Stock · 11,700 shares

Expires 2022-01-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On January 4, 2019, the Reporting Person was granted 23,400 target Performance Restricted Stock Units ("PRSUs"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon Arena's common stock reaching certain Nasdaq "Closing Price" thresholds during the 3-year performance period from Jan. 4, 2019, through Jan. 3, 2022 (the "Performance Period") and satisfaction of a subsequent continuing service requirement. 11,700 of the shares subject to the PRSUs vested in Oct. 2019 (50% of the target amount). On Nov. 25, 2020, another 11,700 of the shares subject to the PRSUs vested (50% of the target amount). The final Closing Price target has been met and an additional 23,400 shares will be issuable pursuant to the PRSUs (200% of the target amount, less the 100% already vested) if the Reporting Person satisfies the subsequent continuing service requirement.

F1 · shares: On January 4, 2019, the Reporting Person was granted 23,400 target Performance Restricted Stock Units ("PRSUs"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon Arena's common stock reaching certain Nasdaq "Closing Price" thresholds during the 3-year performance period from Jan. 4, 2019, through Jan. 3, 2022 (the "Performance Period") and satisfaction of a subsequent continuing service requirement. 11,700 of the shares subject to the PRSUs vested in Oct. 2019 (50% of the target amount). On Nov. 25, 2020, another 11,700 of the shares subject to the PRSUs vested (50% of the target amount). The final Closing Price target has been met and an additional 23,400 shares will be issuable pursuant to the PRSUs (200% of the target amount, less the 100% already vested) if the Reporting Person satisfies the subsequent continuing service requirement.

F1 · derivative.exercise_date: On January 4, 2019, the Reporting Person was granted 23,400 target Performance Restricted Stock Units ("PRSUs"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon Arena's common stock reaching certain Nasdaq "Closing Price" thresholds during the 3-year performance period from Jan. 4, 2019, through Jan. 3, 2022 (the "Performance Period") and satisfaction of a subsequent continuing service requirement. 11,700 of the shares subject to the PRSUs vested in Oct. 2019 (50% of the target amount). On Nov. 25, 2020, another 11,700 of the shares subject to the PRSUs vested (50% of the target amount). The final Closing Price target has been met and an additional 23,400 shares will be issuable pursuant to the PRSUs (200% of the target amount, less the 100% already vested) if the Reporting Person satisfies the subsequent continuing service requirement.

F3 · derivative.underlying_shares: The amount reported in Column 7 of Table II represents the common shares that vested on November 25, 2020. The PRSUs' final Closing Price target has been met and the Reporting Person has a contingent right to receive 23,400 additional common shares if the subsequent continuing service requirement is met.

F1 · balance_after: On January 4, 2019, the Reporting Person was granted 23,400 target Performance Restricted Stock Units ("PRSUs"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon Arena's common stock reaching certain Nasdaq "Closing Price" thresholds during the 3-year performance period from Jan. 4, 2019, through Jan. 3, 2022 (the "Performance Period") and satisfaction of a subsequent continuing service requirement. 11,700 of the shares subject to the PRSUs vested in Oct. 2019 (50% of the target amount). On Nov. 25, 2020, another 11,700 of the shares subject to the PRSUs vested (50% of the target amount). The final Closing Price target has been met and an additional 23,400 shares will be issuable pursuant to the PRSUs (200% of the target amount, less the 100% already vested) if the Reporting Person satisfies the subsequent continuing service requirement.

SEC source: 0001209191-20-060717 · doc4.xml · nonDerivative · entry 2

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,267

F2 · shares: Represents the number of shares withheld by, and surrendered to, Arena relating to tax withholding in connection with the issuance of shares under the PRSUs.

SEC source: 0001209191-20-060717 · doc4.xml · nonDerivative · entry 1

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,450

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On January 4, 2019, the Reporting Person was granted 23,400 target Performance Restricted Stock Units ("PRSUs"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon Arena's common stock reaching certain Nasdaq "Closing Price" thresholds during the 3-year performance period from Jan. 4, 2019, through Jan. 3, 2022 (the "Performance Period") and satisfaction of a subsequent continuing service requirement. 11,700 of the shares subject to the PRSUs vested in Oct. 2019 (50% of the target amount). On Nov. 25, 2020, another 11,700 of the shares subject to the PRSUs vested (50% of the target amount). The final Closing Price target has been met and an additional 23,400 shares will be issuable pursuant to the PRSUs (200% of the target amount, less the 100% already vested) if the Reporting Person satisfies the subsequent continuing service requirement.

SEC source: 0000899243-20-030413 · doc4.xml · derivative · entry 4

Munshi Amit · CIK 0001612551 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,793 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series D Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series D Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Series D Preferred Stock had no expiration date.

F1 · derivative.exercise_date: The Series D Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series D Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Series D Preferred Stock had no expiration date.

F1 · derivative.expiration_date: The Series D Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series D Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Series D Preferred Stock had no expiration date.

SEC source: 0000899243-20-030413 · doc4.xml · nonDerivative · entry 1

Munshi Amit · CIK 0001612551 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,793

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series D Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series D Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Series D Preferred Stock had no expiration date.

SEC source: 0000899243-20-030413 · doc4.xml · derivative · entry 3

Munshi Amit · CIK 0001612551 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,844

Underlying: Common Stock · 4,793 shares

Expires not disclosed

F1 · derivative.exercise_price: The Series D Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series D Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Series D Preferred Stock had no expiration date.

F4 · kind: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.

F1 · derivative.exercise_date: The Series D Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series D Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Series D Preferred Stock had no expiration date.

F1 · derivative.expiration_date: The Series D Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series D Preferred Stock converted into Common Stock at a ratio of 2.59970:1 upon the closing of the Issuer's initial public offering without payment of additional consideration. The Series D Preferred Stock had no expiration date.

SEC source: 0001209191-20-048864 · doc4.xml · derivative · entry 6

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 238,139

Underlying: Common Stock · 50,000 shares

Expires 2023-05-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.

F3 · derivative.exercise_date: The options vested over four years, with 25% of the shares subject to the option vesting on May 11, 2017, and the remainder of the shares vesting quarterly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and were exercisable once vested.

SEC source: 0001209191-20-048864 · doc4.xml · nonDerivative · entry 4

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,750

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.50, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 2 to this Form 4.

SEC source: 0001209191-20-048864 · doc4.xml · nonDerivative · entry 3

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,750

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.

SEC source: 0001209191-20-048864 · doc4.xml · derivative · entry 5

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 288,139

Underlying: Common Stock · 50,000 shares

Expires 2023-05-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.

F3 · derivative.exercise_date: The options vested over four years, with 25% of the shares subject to the option vesting on May 11, 2017, and the remainder of the shares vesting quarterly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and were exercisable once vested.

SEC source: 0001209191-20-048864 · doc4.xml · nonDerivative · entry 2

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,750

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.

SEC source: 0001209191-20-048864 · doc4.xml · nonDerivative · entry 1

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,750

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.

SEC source: 0000899243-20-030413 · doc4.xml · derivative · entry 2

Munshi Amit · CIK 0001612551 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,187

Underlying: Common Stock · 109,187 shares

Expires 2030-06-24

F2 · derivative.exercise_price: On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock ("Stock Split"). This amount has been adjusted to give effect to the Stock Split.

F4 · kind: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3.

F2 · shares: On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock ("Stock Split"). This amount has been adjusted to give effect to the Stock Split.

F3 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on May 19, 2021 and the remainder of the shares vest in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

F2 · derivative.underlying_shares: On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock ("Stock Split"). This amount has been adjusted to give effect to the Stock Split.

F2 · balance_after: On October 20, 2020, the Issuer completed a 2.59970-for-1 stock split of the Issuer's Common Stock ("Stock Split"). This amount has been adjusted to give effect to the Stock Split.

SEC source: 0001209191-20-034542 · doc4.xml · derivative · entry 10

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 338,139

Underlying: Common Stock · 41,861 shares

Expires 2023-05-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.

F6 · derivative.exercise_date: The options vested over four years, with 25% of the shares subject to the option vesting on May 11, 2017, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested.

SEC source: 0001209191-20-034542 · doc4.xml · derivative · entry 9

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,861

Underlying: Common Stock · 8,139 shares

Expires 2024-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.

F5 · derivative.exercise_date: The options vest over four years, with 25% of the shares subject to the option vesting on February 13, 2018, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested.

SEC source: 0001209191-20-034542 · doc4.xml · nonDerivative · entry 7

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,750

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.

F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.97 to $69.68, inclusive.

SEC source: 0001209191-20-034542 · doc4.xml · nonDerivative · entry 6

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,712

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.94 to $68.93, inclusive.

SEC source: 0001209191-20-034542 · doc4.xml · nonDerivative · entry 5

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,740

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.91 to $67.87, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 3, and 4 to this Form 4.

SEC source: 0001209191-20-034542 · doc4.xml · nonDerivative · entry 4

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,750

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.

SEC source: 0001209191-20-034542 · doc4.xml · nonDerivative · entry 3

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,889

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.

SEC source: 0001209191-20-034542 · doc4.xml · derivative · entry 8

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 50,000 shares

Expires 2024-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.

F5 · derivative.exercise_date: The options vest over four years, with 25% of the shares subject to the option vesting on February 13, 2018, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested.

SEC source: 0001209191-20-034542 · doc4.xml · nonDerivative · entry 2

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,750

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.

SEC source: 0001209191-20-034542 · doc4.xml · nonDerivative · entry 1

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,750

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.

SEC source: 0001209191-20-031876 · doc4.xml · derivative · entry 9

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,000

Underlying: Common Stock · 34,800 shares

Expires 2024-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.

F6 · derivative.exercise_date: The options vest over four years, with 25% of the shares subject to the option vesting on February 13, 2018, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested.

SEC source: 0001209191-20-031876 · doc4.xml · nonDerivative · entry 7

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,750

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.

F5 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.00 to $59.22, inclusive.

SEC source: 0001209191-20-031876 · doc4.xml · nonDerivative · entry 6

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,212

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.

F4 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.00 to $58.97, inclusive.

SEC source: 0001209191-20-031876 · doc4.xml · nonDerivative · entry 5

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,143

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.

F3 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.07 to $57.97, inclusive.

SEC source: 0001209191-20-031876 · doc4.xml · nonDerivative · entry 4

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,160

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.19 to $56.99, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 3, 4, and 5 to this Form 4.

SEC source: 0001209191-20-031876 · doc4.xml · nonDerivative · entry 3

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,550

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.

SEC source: 0001209191-20-031876 · doc4.xml · derivative · entry 8

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 149,800

Underlying: Common Stock · 50,000 shares

Expires 2024-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.

F6 · derivative.exercise_date: The options vest over four years, with 25% of the shares subject to the option vesting on February 13, 2018, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested.

SEC source: 0001209191-20-031876 · doc4.xml · nonDerivative · entry 2

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,750

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.

SEC source: 0001209191-20-031876 · doc4.xml · nonDerivative · entry 1

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,750

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.

SEC source: 0000899243-20-010246 · doc4.xml · derivative · entry 1

Munshi Amit · CIK 0001612551 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2030-04-02

F1 · derivative.exercise_date: The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments beginning on the first monthly anniversary of the date of grant, with the first tranche vesting on May 2, 2020, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan.

SEC source: 0001209191-20-015567 · doc4.xml · derivative · entry 1

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 270,000

Underlying: Common Stock · 270,000 shares

Expires 2027-03-01

F1 · derivative.exercise_date: The options vest over four years, with 25% of the shares subject to the option vesting on March 1, 2021, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested.

SEC source: 0001209191-20-009831 · doc4.xml · derivative · entry 3

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 199,800

Underlying: Common Stock · 15,200 shares

Expires 2024-02-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The options vest over four years, with 25% of the shares subject to the option vesting on February 13, 2018, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested.

SEC source: 0001209191-20-009831 · doc4.xml · nonDerivative · entry 2

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,750

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.

SEC source: 0001209191-20-009831 · doc4.xml · nonDerivative · entry 1

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,950

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-007531 · doc4.xml · nonDerivative · entry 1

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,750

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.

SEC source: 0000899243-20-001090 · doc4.xml · derivative · entry 1

Munshi Amit · CIK 0001612551 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-01-09

F1 · derivative.exercise_date: The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments beginning on the first monthly anniversary of the date of grant, with the first tranche vesting on January 9, 2020, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan.

SEC source: 0001209191-19-053332 · doc4.xml · derivative · entry 3

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,100

Underlying: Common Stock · 11,700 shares

Expires 2022-01-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On January 4, 2019, the Reporting Person was granted 23,400 target Performance Restricted Stock Units ("PRSUs"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon the closing price of Arena's common stock (the "Closing Price") reaching certain thresholds during the three-year performance period from January 4, 2019, through January 3, 2022 (the "Performance Period") and satisfaction of a subsequent continuing service requirement. On October 14, 2019, 11,700 of the shares subject to the PRSUs vested (50% of the target amount). Up to an additional 35,100 shares remain issuable pursuant to the PRSUs (200% of the target amount, less the 50% already vested) if all currently outstanding Closing Price targets are met during the Performance Period and subsequent continuing service requirements are met.

F1 · shares: On January 4, 2019, the Reporting Person was granted 23,400 target Performance Restricted Stock Units ("PRSUs"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon the closing price of Arena's common stock (the "Closing Price") reaching certain thresholds during the three-year performance period from January 4, 2019, through January 3, 2022 (the "Performance Period") and satisfaction of a subsequent continuing service requirement. On October 14, 2019, 11,700 of the shares subject to the PRSUs vested (50% of the target amount). Up to an additional 35,100 shares remain issuable pursuant to the PRSUs (200% of the target amount, less the 50% already vested) if all currently outstanding Closing Price targets are met during the Performance Period and subsequent continuing service requirements are met.

F1 · derivative.exercise_date: On January 4, 2019, the Reporting Person was granted 23,400 target Performance Restricted Stock Units ("PRSUs"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon the closing price of Arena's common stock (the "Closing Price") reaching certain thresholds during the three-year performance period from January 4, 2019, through January 3, 2022 (the "Performance Period") and satisfaction of a subsequent continuing service requirement. On October 14, 2019, 11,700 of the shares subject to the PRSUs vested (50% of the target amount). Up to an additional 35,100 shares remain issuable pursuant to the PRSUs (200% of the target amount, less the 50% already vested) if all currently outstanding Closing Price targets are met during the Performance Period and subsequent continuing service requirements are met.

F4 · derivative.underlying_shares: The amount reported in Column 7 of Table II represents the common shares that vested on October 14, 2019. Under the PRSUs, the Reporting Person has a contingent right to receive up to 35,100 additional common shares if all currently outstanding Closing Price targets are met during the Performance Period and subsequent continuing service requirements are met.

F1 · balance_after: On January 4, 2019, the Reporting Person was granted 23,400 target Performance Restricted Stock Units ("PRSUs"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon the closing price of Arena's common stock (the "Closing Price") reaching certain thresholds during the three-year performance period from January 4, 2019, through January 3, 2022 (the "Performance Period") and satisfaction of a subsequent continuing service requirement. On October 14, 2019, 11,700 of the shares subject to the PRSUs vested (50% of the target amount). Up to an additional 35,100 shares remain issuable pursuant to the PRSUs (200% of the target amount, less the 50% already vested) if all currently outstanding Closing Price targets are met during the Performance Period and subsequent continuing service requirements are met.

SEC source: 0001209191-19-053332 · doc4.xml · nonDerivative · entry 2

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,879

F3 · shares: Represents the number of shares withheld by, and surrendered to, Arena relating to tax withholding in connection with the issuance of shares under the PRSUs.

SEC source: 0001209191-19-053332 · doc4.xml · nonDerivative · entry 1

Munshi Amit · CIK 0001612551 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,450

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: On January 4, 2019, the Reporting Person was granted 23,400 target Performance Restricted Stock Units ("PRSUs"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon the closing price of Arena's common stock (the "Closing Price") reaching certain thresholds during the three-year performance period from January 4, 2019, through January 3, 2022 (the "Performance Period") and satisfaction of a subsequent continuing service requirement. On October 14, 2019, 11,700 of the shares subject to the PRSUs vested (50% of the target amount). Up to an additional 35,100 shares remain issuable pursuant to the PRSUs (200% of the target amount, less the 50% already vested) if all currently outstanding Closing Price targets are met during the Performance Period and subsequent continuing service requirements are met.

F2 · balance_after: Includes 62 shares acquired on June 30, 2017, pursuant to the 2009 Arena Employee Stock Purchase Plan.

SEC source: 0000899243-19-014139 · doc4.xml · derivative · entry 1

Munshi Amit · CIK 0001612551 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2029-05-16

F1 · derivative.exercise_date: The option vests in forty-eight (48) equal monthly installments on the 16th day of each month, with the first tranche vesting on June 16, 2019, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan.